The Company listed on the Australian Securities Exchange in 2007 as Actinogen Limited. In 2014, the Company acquired Corticrine from Edinburgh University, a company focused on the development of brain penetrant 11β-HSD1 enzyme inhibitors for the treatment of cognitive impairment. The lead drug in development by Corticrine was Xanamem. Corticrine received A$25m support from the Seeding Drug Discovery program of the Wellcome Trust and the University of Edinburgh and successfully completed a Phase 1 single ascending dose (SAD) study of UE2343 (Xanamem) in healthy human volunteers. Corticrine then became part of Actinogen Limited and the company subsequently rebranded to become Actinogen Medical in 2015.

Suite 901, Level 9, 109 Pitt Street, Sydney, NSW 2000

The share registry is managed by Automic Pty Ltd. To login and access your holding information, please go to: https://investor.automic.com.au

Shareholders can check their shareholdings by logging into the Automic investor portal: https://investor.automic.com.au
For queries, contact Automic at 1300 288 664 (Australia) or +61 2 9698 5414 (international), or email hello@automicgroup.com.au.

All company shares are traded on the Australian Securities Exchange (ASX) and can be bought or sold through a licensed stockbroker. For more details visit: ASX: Buying & Selling Shares

Non-Australian residents should contact a licensed stockbroker that offers cross-border services with Australia or use an online trading platform that provides access to the ASX. Please note ACW is only listed on the Australian Securities Exchange.

Recent annual reports are available on the Actinogen website at https://actinogen.com.au/about-us/#annual_reports

Visit www.asx.com.au and search the ticker symbol ACW. A 20-minute delayed share price graph is also available in our Investor Centre.

The ASX ticker code for the Company is ASX:ACW

The latest financial reports can be found in our Results Centre.

The Company’s financial year ends on 30th June.

Actinogen typically holds its AGM towards the end of November. Shareholders are notified 28 days in advance, usually in September or October.

The Company’s auditors are Ernst and Young.

K&L Gates

Peter Webse
Email: pwebse@governancecorp.com.au

The Corporate Governance Statement and related policies are available at: https://actinogen.com.au/corporate-governance/

The Company does not currently have a dividend policy, as it is not yet revenue-generating. The Board regularly assesses this in line with capital requirements and growth opportunities.